As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.
How will cancer centers counsel patients who walk through the doors with MCD test results? Under what circumstances can cancer physicians rely on this technology? What role will they play in determining the potential of these tests to affect health outcomes?
These burning questions were front and center on the October episode of The Directors, a monthly series on The Cancer Letter Podcast which focuses on the problems that keep directors of cancer centers up at night.
“I think there’s room for us to have some caution, because we still don’t know what [a Galleri result] is actually saying,” Monica L. Baskin, director of VCU Massey Cancer Center, said in the October episode of The Directors. “It sort of signals that something is there, but the key is really in the follow-up. How can we really go in and have the diagnostics to understand?”
Baskin appeared on The Directors with Robert L. Ferris, executive director of the UNC Lineberger Comprehensive Cancer Center and chief of Oncology Clinical Services for UNC Health. The podcast is moderated by Paul Goldberg, editor and publisher of The Cancer Letter and sponsored by the American Society of Clinical Oncology.
VCU and UNC are among the sites of the NCI Vanguard trial, which seeks to gauge the impact of the Avantect and Shield tests (not the Galleri test) and the patient benefit they can provide. The tests are called alternatively the multicancer detection tests—called MCDs for short—or multicancer early detection tests—or MCEDs.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Cancer Letter. Innehållet i podden är skapat av The Cancer Letter och inte av,
eller tillsammans med, Poddtoppen.
